Trial · NCT07347444
Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
NCT07347444, Phase 2, Not yet recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma. Trials, record NCT07347444. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07347444
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
- NCT number
- NCT07347444
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Acral Melanoma, Mucosal Melanoma
- Interventions
- Iparomlimab and Tuvoraleimab injection+Bev+nab-PC
- First posted
- 2026-01-16
- Last updated
- 2026-01-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | up to 2 years | Defined as the percentage of participants in the analysis population who experienced a Complete Response or a Partial Response and was assessed using RECIST 1.1 based on investigator evaluation. |
| Secondary | Disease control rate (DCR) | up to 2 years | Defined as the percentage of participants in the analysis population who achieved Complete Response, Partial Response, or Stable Disease, as assessed by the investigator according to RECIST 1.1 criteria. |
| Secondary | Duration of Response (DoR) | up to 2 years | Defined as the time from the first documented confirmed response (CR or PR) to the first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first. |
| Secondary | Time to Response (TTR) | up to 2 years | Defined as the time from the first administration of the investigational drug to the first occurrence of Complete Response (CR) or Partial Response (PR). |
| Secondary | Progression-Free Survival (PFS) | up to 2 years | Defined as the time from the initiation of treatment until the first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | up to 2 years | Defined as the time from the initiation of treatment until death from any cause. |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | up to 2 years | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07347444
GET https://conductscience.org/api/trials/v1/NCT07347444/registered